Oklahoma is currently home to 859 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Oklahoma City, Tulsa, Norman and Edmond. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of ALTO-300 in MDD
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/21/2025
Locations: Site 195, Oklahoma City, Oklahoma
Conditions: Major Depressive Disorder
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
Recruiting
This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing
Gender:
ALL
Ages:
Between 6 months and 72 months
Trial Updated:
07/21/2025
Locations: Allergy, Asthma and Clinical Research Center, Oklahoma City, Oklahoma
Conditions: Recurrent Wheezing, Wheezing Lower Respiratory Illness
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Ou Health - Stephenson Cancer Center /ID# 269525, Oklahoma City, Oklahoma
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Recruiting
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Stephenson Cancer Center at OU Health, Oklahoma City, Oklahoma
Conditions: Endometrial Adenocarcinoma
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Recruiting
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2025
Locations: Dean McGee Eye Institute, Oklahoma City, Oklahoma
Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)
Recruiting
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. It is known to cause a variety of cancers including cancer of the cervix. Even though there are ways to detect cervical cancer early, many individuals do not un... Read More
Gender:
FEMALE
Ages:
25 years and above
Trial Updated:
07/18/2025
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Cervical Carcinoma, Human Papillomavirus Infection
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Recruiting
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
Recruiting
The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Study details include: * The study duration will be up to 15 weeks. * The treatment duration will be 12 weeks. * The visit frequency will be once every 4 weeks, with 3 clinic visits and 2 video calls in total.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/18/2025
Locations: Research Site, Oklahoma City, Oklahoma
Conditions: Mild Asthma
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Recruiting
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Advanced Solid Tumor
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Recruiting
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Advanced or Metastatic Colorectal Cancer
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Alliance for Multispecialty Research, LLC, Norman, Oklahoma
Conditions: Type 1 Diabetes, Obesity, Overweight
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Recruiting
The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are: 1. what is the maximum tolerated dose and recommended dose for phase 2? 2. how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Squamous Cell Carcinoma of Head and Neck, Endometrial Cancer, HR+/HER2-negative Breast Cancer, Bladder Cancer